Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07045298 · ClinicalTrials.gov registry record · NA
CGM Use in Heart Failure
A NA study, sponsored by Emory University.
- Not yet
- Registry status
- NA
- Development phase
- 140
- Enrollment target
NCT07045298 is a NA study that has not yet begun recruiting, run by Emory University. The registered enrollment target is 140 participants.
The verdict
NCT07045298, a NA study, has not yet begun recruiting, sponsored by Emory University.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 140 participants
- Enrollment target
Study Summary
Heart failure (HF) is a major cause of hospital admissions in the US, with over 6 million hospital days annually. More than 40% of hospitalized patients with HF have diabetes mellitus (DM), which increases the risk of recurrent hospitalizations for HF with reduced and preserved ejection fraction by more than two-fold. Current methods for assessing glycemic control do not consider fluctuations in blood glucose levels, known as glycemic variability. High glycemic variability is a poor prognostic marker for HF re-hospitalizations. Given the significant prevalence and impact of DM in individuals with HF, it is crucial to examine whether improving glycemic control and avoiding hypoglycemia could lead to a decrease in HF readmissions. Real-time continuous glucose monitoring (rt-CGM), which provides glucose measurements as frequently as every 5 minutes, has improved glycemic control in insulin-treated adults with DM compared to the standard of care, capillary point-of-care blood glucose testing (POC). Researchers will monitor participants during their hospital stay and 3 months after discharge.
Interventions
- DEVICE Libre 2 rt-CGM
- DIAGNOSTIC_TEST POC BG + Blinded CGM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2026-04 |
| Est. Completion | 2027-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07045298
The ClinicalTrials.gov registry entry for NCT07045298 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Libre 2 rt-CGM is the first listed.
NCT07045298 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07045298 about?
NCT07045298 is a clinical study titled "CGM Use in Heart Failure". Heart failure (HF) is a major cause of hospital admissions in the US, with over 6 million hospital days annually. More than 40% of hospitalized patients with HF have diabetes mellitus (DM), which increases the risk of recurrent hospitalizations for HF with reduced and preserved ejection fraction by...
What is the current status of trial NCT07045298?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 140 participants. The study started on 2026-04. Estimated completion is 2027-04.
What interventions are being tested in trial NCT07045298?
The interventions under investigation include: Libre 2 rt-CGM (DEVICE), POC BG + Blinded CGM (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07045298?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.